The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Open accessAbstract
PURPOSE: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics. METHODS: Patients with relapsed/refractory MCL (one to five prior therapies, including prior BTKi exposure) received a single infusion of KTE-X19 (2 × 10 6 CAR T cells/kg). RESULTS: After a median follow-up of 35.6 months, the objective response rate among all 68 treated patients was 91% (95% CI, 81.8 to 96.7) with 68% complete responses (95% CI, 55.2 to 78.5); medians for duration of response, progression-free survival, and overall survival were 28.2 months (95% CI, 13.5 to 47.1), 25.8 months (95% CI, 9.6 to 47.6), and 46.6 months (95% CI, 24.9 to not estimable), respectively. Post hoc analyses showed that objective response rates and ongoing response rates were consistent among prespecified subgroups by prior BTKi exposure or high-risk characteristics. In an exploratory analysis, patients with prior bendamustine benefited from KTE-X19, but showed a trend toward attenuated T-cell functionality, with more impact of bendamustine given within 6 versus 12 months of leukapheresis. Late-onset toxicities were infrequent; only 3% of treatment-emergent adverse events of interest in ZUMA-2 occurred during this longer follow-up period. Translational assessments revealed associations with long-term benefits of KTE-X19 including high-peak CAR T-cell expansion in responders and the predictive value of minimal residual disease for relapse. CONCLUSION: These data, representing the longest follow-up of CAR T-cell therapy in patients with MCL to date, suggest that KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL and may also benefit those with high-risk characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationKTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Self-citationRummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationDreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002394 · Cited by 489
Self-citationIbrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
Ibrutinib treatment improves T cell number and function in CLL patients
Long, M., Beckwith, K., Do, P., Mundy, B. L., Gordon, A., Lehman, A. M., Maddocks, K. J., Cheney, C., Jones, J. A., Flynn, J. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89756 · Cited by 388
Postibrutinib outcomes in patients with mantle cell lymphoma
Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., Rule, S., Advani, R., Iberri, D., Phillips, T., et al. (2016) · Blood · doi:10.1182/blood-2015-10-673145 · Cited by 294
Self-citationMantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Jain, P., & Wang, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25487 · Cited by 274
Self-citationHiddemann, W., Barbui, A. M., Canales, M. A., Cannell, P. K., Collins, G. P., Dürig, J., Forstpointner, R., Herold, M., Hertzberg, M., Klanova, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8960 · Cited by 240
Ruella, M., Kenderian, S. S., Shestova, O., Fraietta, J. A., Qayyum, S., Zhang, Q., Maus, M. V., Liu, X., Nunez-Cruz, S., Klichinsky, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1527 · Cited by 188
Cheah, C. Y., Chihara, D., Romaguera, J. E., Fowler, N. H., Seymour, J. F., Hagemeister, F. B., Champlin, R. E., & Wang, M. L. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv111 · Cited by 177
Self-citationBlastic variant of mantle cell lymphoma: a rare but highly aggressive subtype
Bernard, M., Gressin, R., Lefrère, F., Drénou, B., Branger, B., Caulet-Maugendre, S., Tass, P., Brousse, N., Valensi, F., Milpied, N., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402272 · Cited by 167
Rule, S. A., Dreyling, M. H., Goy, A. H., Heß, G., Auer, R. L., Kahl, B. S., Cavazos, N., Liu, B., Yang, S., Clow, F., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14870 · Cited by 160
Self-citationThe Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma
Katzenberger, T., Petzoldt, C., Höller, S., Mäder, U., Kalla, J., Adam, P., Ott, M. M., Müller‐Hermelink, H. K., Rosenwald, A., & Ott, G. (2006) · Blood · doi:10.1182/blood-2005-10-4079 · Cited by 156
Jain, P., Kanagal‐Shamanna, R., Zhang, S., Ahmed, M., Ghorab, A., Zhang, L., Ok, C. Y., Li, S., Hagemeister, F. B., Zeng, D., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15567 · Cited by 128
Self-citationBlastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
Dreyling, M. H., Klapper, W., & Rule, S. A. (2018) · Blood · doi:10.1182/blood-2017-08-737502 · Cited by 90
Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy
McCulloch, R., Visco, C., Eyre, T. A., Frewin, R., Phillips, N., Tucker, D. L., Quaglia, F. M., McMillan, A., Lambert, J., Crosbie, N., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16416 · Cited by 76
Epperla, N., Hamadani, M., Cashen, A. F., Ahn, K. W., Oak, E., Kanate, A. S., Calzada, O., Cohen, J. B., Farmer, L., Ghosh, N., et al. (2017) · Hematological Oncology · doi:10.1002/hon.2380 · Cited by 71
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches
Silkenstedt, E., Linton, K., & Dreyling, M. H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17419 · Cited by 71
Matasar, M. J., Czuczman, M. S., Rodriguez, M. A., Fennessy, M., Shea, T. C., Spitzer, G., Lossos, I. S., Kharfan‐Dabaja, M. A., Joyce, R., Fayad, L., et al. (2013) · Blood · doi:10.1182/blood-2012-12-472027 · Cited by 66
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
Jain, P., Dreyling, M. H., Seymour, J. F., & Wang, M. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02287 · Cited by 53
Self-citationSmardova (2010) · International Journal of Oncology · doi:10.3892/ijo_00000545 · Cited by 47
Eskelund, C. W., Dimopoulos, K., Kolstad, A., Glimelius, I. C., Räty, R., Gjerdrum, L. M. R., Sonnevi, K., Josefsson, P. L., Nilsson‐Ehle, H., Bentzen, H., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000510 · Cited by 34
Duell, J., Lukic, D. S., Karg, M. M., Reusch, U., Koch, J., Zhukovsky, E. A., Rajkovic, E., Treder, M., Rasche, L., Eisele, F., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000267 · Cited by 24
Self-citation
Cited by
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 359
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
Cordas dos Santos, D. M., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I. M., Subklewe, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03084-6 · Cited by 287
Iacoboni, G., Navarro, V., Martín-López, A. Á., Rejeski, K., Kwon, M., Jalowiec, K. A., Amat, P., Reguera-Ortega, J. L., Gallur, L., Blumenberg, V., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01097 · Cited by 143
Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders
Thompson, P. A., & Tam, C. (2023) · Blood Journal · doi:10.1182/blood.2023020240 · Cited by 42
Metadata
- Authors
- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M. J., Bouabdallah, K., Khanal, R., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., Fang, X., Shen, R. R., Siddiqi, R., Kloos, I., & Reagan, P. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2023-01-20
- Volume
- 41
- Issue
- 3
- Pages
- 555-567
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4281901970
- Cited by
- 331
- References
- 31
- FWCI
- 24.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.